Mountain View, CA, May 15, 2003
IMPAC Medical Systems,
Inc. (NASDAQ:IMPC) and the National Cancer Registrars
Association’s (NCRA) Journal of Registry Management (JRM) are
proud to announce the recipients of the 2002 IMPAC-JRM Best Paper
Award. Awards will be presented to the authors of the
prize-winning papers during NCRA’s Annual Education Conference on
Friday, May 16, 2003, in Pittsburgh, PA.
The Best Paper Award was won for “Experience in Developing E-path
Cancer Reporting For Rapid Case Ascertainment” by Dennis Deapen,
Herman R. Menck, Ina L. Ervin, Meryl Leventhal, and Joyce C.
Niland, JRM Summer 2002.
Two papers tied for Honorable Mention: “The Effect of Seasonal
Residence on Cancer Incidence”, by Francis P. Boscoe, and Colleen
C. McLaughlin, published in the Spring 2002 issue of JRM and “The
Impact of E-path Technology on the Ontario Cancer Registry
Operations”, by Darlene Dale, Jack K. Golabek, and Nelson Chong,
published in the Summer 2002 issue of JRM.
All papers appearing in the Journal of Registry Management in 2002
were eligible for consideration. The IMPAC/JRM Best Paper
Selection Committee for 2002 included Susan T. Gershman, MS, MPH,
PhD, CTR, director, Massachusetts Cancer Registry; Carol Johnson,
CTR, data quality specialist, SEER Program; Carol L. Lowenstein,
MBA, CTR, rapid case coordinator, Harvard School of Public Health
and Dana-Farber/Harvard Cancer Center; Jerri Linn Phillips, MA,
CTR, cancer data and quality management specialist, American
College of Surgeons; and Theola Rarick, CTR oncology registry
administrator, Holden Comprehensive Cancer Center and University
of Iowa Health Care.
“The award is granted to authors publishing the highest quality
papers addressing topics which are significant to registry
professionals,” stated Amy Fremgen, PhD, CTR, editor, Journal of
Registry Management. “On behalf of the journal and the NCRA, we
appreciate IMPAC for making these awards possible and their
continuing support of cancer registry work.”
“IMPAC is honored to sponsor the IMPAC-JRM Best Paper Award,” said
Donna Getreuer, RN, MSN, CTR, and IMPAC’s senior product manager
for cancer registry systems. “We are pleased to support JRM’s
commitment to acknowledge authors for their exemplary work in the
field of medical registry.”
About
National Cancer Registrars Association
The National Cancer Registrars Association (NCRA) is the
professional organization of those in the cancer registration and
surveillance discipline. NCRA advances professional development by
providing educational opportunities for continuous learning. NCRA
promotes accurate, timely data as mandated by federal and state
law for cancer research and other uses of clinical data. NCRA’s
liaisons provide representation to other professional, government
and non-profit organizations that may impact the cancer registry
profession, cancer control and surveillance.
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. is a leading provider of specialized
IT solutions that streamline both clinical and business operations
to help improve the process of delivering quality patient care.
With open integration to multiple healthcare data and imaging
systems, IMPAC offers a comprehensive IT solution that includes
specialized electronic charting, full-featured practice
management, clinical laboratory management, and outcomes
reporting. Supporting over 1500 installations worldwide, IMPAC
delivers practical solutions that deliver better overall
communication, process efficiency and quality patient care. For
more information about IMPAC Medical Systems’ products and
services, please call 650-623-8800 or visit www.impac.com.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's business strategy, timing of, and plans
for, the introduction of new products and enhancements, future
sales, market growth and direction, competition, market share,
revenue growth, operating margins and profitability. All forward
looking statements included in this document are based upon
information available to the Company as of the date hereof, and
the Company assumes no obligation to update any such forward
looking statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, and other factors and risks discussed in
the Company's Final Prospectus dated November 20, 2002 and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
